Targeting impulsivity in Parkinson’s disease using atomoxetine
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Noradrenergic dysfunction may play a significant role in cognition in Parkinson's disease due to the early degeneration of the locus coeruleus. Converging evidence from patient and animal studies points to the role of noradrenaline in dopaminergically insensitive aspects of the parkinsonian dysexecutive syndrome, yet the direct effects of noradrenergic enhancement have not to date been addressed. Our aim was to directly investigate these, focusing on impulsivity during response inhibition and decision making. To this end, we administered 40 mg atomoxetine, a selective noradrenaline re-uptake inhibitor to 25 patients with Parkinson's disease (12 female /13 male; 64.4 ± 6.9 years old) in a double blind, randomized, placebo controlled design. Patients completed an extensive battery of neuropsychological tests addressing response inhibition, decision-making, attention, planning and verbal short term memory. Atomoxetine improved stopping accuracy on the Stop Signal Task [F(1,19) = 4.51, P = 0.047] and reduced reflection impulsivity [F(1,9) = 7.86, P = 0.02] and risk taking [F(1,9) = 9.2, P = 0.01] in the context of gambling. The drug also conferred effects on performance as a function of its measured blood plasma concentration: it reduced reflection impulsivity during information sampling [adjusted R(2) = 0.23, F(1,16) = 5.83, P = 0.03] and improved problem solving on the One Touch Stockings of Cambridge [adjusted R(2) = 0.29, F(1,17) = 8.34, P = 0.01]. It also enhanced target sensitivity during sustained attention [F(1,9) = 5.33, P = 0.046]. The results of this exploratory study represent the basis of specific predictions in future investigations on the effects of atomoxetine in Parkinson's disease and support the hypothesis that targeting noradrenergic dysfunction may represent a new parallel avenue of therapy in some of the cognitive and behavioural deficits seen in the disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A New Method for Measuring Daytime Sleepiness: The Epworth Sleepiness Scale
Johns, M. W. (1991) · Sleep · doi:10.1093/sleep/14.6.540 · Cited by 17,364 · cited 1×
“Patients completed the State and Trait Anxiety Inventory (Spielberger et al., 1983), Epworth Sleepiness Scale (Johns, 1991), Beck Depression Inventory (Beck et al., 1961) and verbal (FAS) and semantic (animals) fluency (Benton, 1968).”
Method(1987) · American Journal of Psychiatry · doi:10.1176/ajp.144.9.1184 · Cited by 2,948
Evenden, J. L. (1999) · Psychopharmacology · doi:10.1007/pl00005481 · Cited by 2,044 · cited 2×
“…disorder using a range of tasks probing different facets of the construct: response inhibition, reflection impulsivity, delay discounting, and delay aversion rely on different neurobiological substrates in terms of underlying neurochemistry and circuitry (Evenden, 1999; Robbins and Arnsten, 2009).”
MethodThe use of analogue scales in rating subjective feelings
BOND, A., & LADER, M. (1974) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1974.tb02285.x · Cited by 1,972
Functional role of the supplementary and pre-supplementary motor areas
Nachev, P., Kennard, C., & Husain, M. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2478 · Cited by 1,928
Stop-signal inhibition disrupted by damage to right inferior frontal gyrus in humans
Aron, A. R., Fletcher, P. C., Bullmore, E. T., Sahakian, B. J., & Robbins, T. W. (2003) · Nature Neuroscience · doi:10.1038/nn1003 · Cited by 1,771 · cited 2×
“2B) but not the second session (F5 1).”
BackgroundSelf-citationOn the ability to inhibit simple and choice reaction time responses: A model and a method.
Logan, G. D., Cowan, W. B., & Davis, K. A. (1984) · Journal of Experimental Psychology: Human Perception and Performance · doi:10.1037/0096-1523.10.2.276 · Cited by 1,542
Bymaster, F. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(02)00346-9 · Cited by 1,123
Rogers, R. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00091-8 · Cited by 1,101 · cited 5×
“In the Cambridge Gamble Task (Rogers et al., 1999) participants decide whether a randomly hidden token is more likely to be in a red or blue box within a display of 10 boxes (the ratio of which varies within a display of 10 boxes), and place bets (in ascending and descending order) on their choice being correct.”
BackgroundInfluentialRubia, K., Russell, T., Overmeyer, S., Brammer, M. J., Bullmore, E. T., Sharma, T., Simmons, A., Williams, S. C. R., Giampietro, V., Andrew, C. M., et al. (2001) · NeuroImage · doi:10.1006/nimg.2000.0685 · Cited by 999 · cited 2×
“Evidence from neuropsychological studies (Aron et al., 2003a; Rieger et al., 2003; Floden and Stuss, 2006), neuroimaging (Rubia et al., 2001; Aron et al., 2003b; Nachev et al., 2008; Pauls et al., 2012) and deep brain stimulation (Jahanshahi et al., 2000; van den Wildenberg et al., 2006; Ballanger…”
BackgroundThe Neuropsychopharmacology of Fronto-Executive Function: Monoaminergic Modulation
Robbins, T. W., & Arnsten, A. F. T. (2009) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.051508.135535 · Cited by 957
Self-citation‘Frontal' cognitive function in patients with Parkinson's disease ‘on' and ‘off' levodopa
GOTHAM, A. M., BROWN, R. G., & MARSDEN, C. D. (1988) · Brain · doi:10.1093/brain/111.2.299 · Cited by 835
Pathoanatomy of Parkinson’s disease
Braak, H., & Braak, E. (2000) · Journal of Neurology · doi:10.1007/pl00007758 · Cited by 693 · cited 1×
“At clinical onset, patients present with unilateral motor deficits largely reflecting dopaminergic and cholinergic dysfunction due to degenerative events in the substantia nigra and midbrain nuclei commencing up to 5 years earlier (Braak and Braak, 2000; Braak et al., 2002).”
BackgroundHorse-race model simulations of the stop-signal procedure
Band, G. P. H., van der Molen, M. W., & Logan, G. D. (2003) · Acta Psychologica · doi:10.1016/s0001-6918(02)00079-3 · Cited by 687
Association of dopamine agonist use with impulse control disorders in Parkinson disease
Weintraub, D., Siderowf, A. D., Potenza, M. N., Goveas, J., Morales, K. H., Duda, J. E., Moberg, P. J., & Stern, M. B. (2006) · Archives of Neurology · doi:10.1001/archneur.63.7.969 · Cited by 662 · cited 2×
“…conditions treated with dopamine agonists, such as restless leg syndrome (Cornelius et al., 2010); in Parkinson’s disease, these agents increase the risk of impulse control disorder expression (Weintraub et al., 2006) but they do not unequivocally cause it (Evans et al., 2005; Voon et al., 2007).”
BackgroundA timeline for Parkinson's disease
Hawkes, C. H., Del Tredici, K., & Braak, H. (2010) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2009.08.007 · Cited by 594
Neurochemical Modulation of Response Inhibition and Probabilistic Learning in Humans
Chamberlain, S. R., Müller, U., Blackwell, A. D., Clark, L., Robbins, T. W., & Sahakian, B. J. (2006) · Science · doi:10.1126/science.1121218 · Cited by 573 · cited 5×
“In humans, enhancing noradrenaline neurotransmission using the selective noradrenaline re-uptake inhibitor atomoxetine improves stop signal reaction time in healthy individuals (Chamberlain et al., 2006) as well as in adult patients with attention deficit hyperactivity disorder (Chamberlain et al.”
BackgroundMethodResultInfluentialSelf-citationSerotonin selectively influences moral judgment and behavior through effects on harm aversion
Crockett, M. J., Clark, L., Hauser, M. D., & Robbins, T. W. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009396107 · Cited by 526 · cited 2×
“, 2004) and young healthy volunteers (Crockett et al., 2010), and appears to be specific to the action of atomoxetine, as methylphenidate only improves response latency (Elliott et al.”
BackgroundSelf-citationLearning and cognitive flexibility: frontostriatal function and monoaminergic modulation
Kehagia, A. A., Murray, G. K., & Robbins, T. W. (2010) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2010.01.007 · Cited by 398 · cited 2×
“Specifically, we have suggested that aspects of the Parkinson’s disease dysexecutive syndrome may also reflect this longstanding noradrenergic deficit (Kehagia et al., 2009, 2010a, b).”
BackgroundSelf-citationEffects of methylphenidate on spatial working memory and planning in healthy young adults
Elliott, R., Sahakian, B. J., Matthews, K., Bannerjea, A., Rimmer, J., & Robbins, T. W. (1997) · Psychopharmacology · doi:10.1007/s002130050284 · Cited by 389
Self-citationAssessing the abuse potential of methylphenidate in nonhuman and human subjects: a review
Kollins, S. H., MacDonald, E. K., & Rush, C. R. (2001) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(01)00464-6 · Cited by 365
Robinson, E. S. J., Eagle, D. M., Mar, A. C., Bari, A., Banerjee, G., Jiang, X., Dalley, J. W., & Robbins, T. W. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301487 · Cited by 359 · cited 1×
“In the rat, atomoxetine has been shown to enhance inhibition on the stop signal task, as well as the fivechoice serial reaction time and delay discounting tasks (Robinson et al., 2008).”
Self-citationInhibitory control is slowed in patients with right superior medial frontal damage
Floden, D., & Stuss, D. T. (2006) · Journal of Cognitive Neuroscience · doi:10.1162/jocn.2006.18.11.1843 · Cited by 302 · cited 2×
“2B) but not the second session (F5 1).”
BackgroundDopamine-dependent frontostriatal planning deficits in early Parkinson's disease.
Owen, A. M., Sahakian, B. J., Hodges, J. R., Summers, B. A., Polkey, C. E., & Robbins, T. W. (1995) · Neuropsychology · doi:10.1037//0894-4105.9.1.126 · Cited by 294
Self-citationAtomoxetine improved response inhibition in adults with attention deficit/hyperactivity disorder
Chamberlain, S. R., del Campo, N., Dowson, J., Müller, U., Clark, L., Robbins, T. W., & Sahakian, B. J. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.03.003 · Cited by 288 · cited 5×
“The 40 mg dose could be considered conservative, compared to studies in healthy subjects and adult patients with attention deficit hyperactivity disorder using doses up to 60 mg (Chamberlain et al., 2006, 2007; Gilbert et al., 2006) and 90 mg (Heil et al., 2002).”
BackgroundResultInfluentialSelf-citationInhibition of ongoing responses in patients with Parkinson's disease
Gauggel, S., Rieger, M., & Feghoff, T.-A. (2004) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2003.016469 · Cited by 284 · cited 4×
“Previous studies comparing patients with Parkinson’s disease to controls demonstrated longer stop signal reaction (Gauggel et al., 2004; Obeso et al., 2011a) and no effects of dopaminergic medication on any Stop Signal Task measure (Obeso et al., 2011b; Alegre et al., 2013).”
BackgroundResultInfluentialThe psychometric tradition: Developing the wechsler adult intelligence scale
Wechsler, D. (1981) · Contemporary Educational Psychology · doi:10.1016/0361-476x(81)90035-7 · Cited by 274
van den Wildenberg, W. P. M., van Boxtel, G. J. M., van der Molen, M. W., Bosch, D. A., Speelman, J. D., & Brunia, C. H. M. (2006) · Journal of Cognitive Neuroscience · doi:10.1162/jocn.2006.18.4.626 · Cited by 265 · cited 1×
“…(Rubia et al., 2001; Aron et al., 2003b; Nachev et al., 2008; Pauls et al., 2012) and deep brain stimulation (Jahanshahi et al., 2000; van den Wildenberg et al., 2006; Ballanger et al., 2009; Alegre et al., 2013; Favre et al., 2013) has led to a broad functional characterization of a…”
BackgroundAtomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease
Weintraub, D., Mavandadi, S., Mamikonyan, E., Siderowf, A. D., Duda, J. E., Hurtig, H. I., Colcher, A., Horn, S. S., Nazem, S., Ten Have, T. R., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181ebdd79 · Cited by 255 · cited 5×
“A dose of 40 mg was used to ensure tolerability based on previous studies (Jankovic, 2009; Marsh et al., 2009; Weintraub et al., 2010b).”
BackgroundMethodInfluentialROGERS, D., LEES, A. J., SMITH, E., TRIMBLE, M., & STERN, G. M. (1987) · Brain · doi:10.1093/brain/110.3.761 · Cited by 218
Reliability and plasticity of response inhibition and interference control
Wöstmann, N. M., Aichert, D. S., Costa, A., Rubia, K., Möller, H.-J., & Ettinger, U. (2013) · Brain and Cognition · doi:10.1016/j.bandc.2012.09.010 · Cited by 217 · cited 1×
“In Parkinson’s disease, atomoxetine led to a shift to a more conservative response strategy, so that patients favoured stopping accuracy over speed, despite the tracking function and experimental instructions (Sylwan, 2004; Wostmann et al., 2013).”
BackgroundBari, A., Eagle, D. M., Mar, A. C., Robinson, E. S. J., & Robbins, T. W. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1537-0 · Cited by 194
Self-citationInhibition of ongoing responses following frontal, nonfrontal, and basal ganglia lesions.
Rieger, M., Gauggel, S., & Burmeister, K. (2003) · Neuropsychology · doi:10.1037/0894-4105.17.2.272 · Cited by 183 · cited 2×
“Evidence from neuropsychological studies (Aron et al., 2003a; Rieger et al., 2003; Floden and Stuss, 2006), neuroimaging (Rubia et al., 2001; Aron et al., 2003b; Nachev et al., 2008; Pauls et al., 2012) and deep brain stimulation (Jahanshahi et al., 2000; van den Wildenberg et al., 2006; Ballanger…”
Backgrounddel Campo, N., Fryer, T. D., Hong, Y. T., Smith, R., Brichard, L., Acosta-Cabronero, J., Chamberlain, S. R., Tait, R., Izquierdo, D., Regenthal, R., et al. (2013) · Brain · doi:10.1093/brain/awt263 · Cited by 113 · cited 1×
“…disease, methylphenidate was shown to reduce apathy (Chatterjee and Fahn, 2002; Moreau et al., 2012) and daytime sleepiness (Devos et al., 2007; Moreau et al., 2012) presumably reflecting its noradrenalinergic impact (although dopaminergic effects cannot be discounted; del Campo et al., 2013).”
BackgroundSelf-citationGilbert, D. L., Ridel, K. R., Sallee, F. R., Zhang, J., Lipps, T. D., & Wassermann, E. M. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300806 · Cited by 97
Bari, A., & Aston-Jones, G. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.07.020 · Cited by 85
Methylphenidate Effects on Prefrontal Functioning During Attentional-Capture and Response Inhibition
Pauls, A. M., O'Daly, O. G., Rubia, K., Riedel, W. J., Williams, S. C. R., & Mehta, M. A. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.03.028 · Cited by 57 · cited 2×
“…(Aron et al., 2003a; Rieger et al., 2003; Floden and Stuss, 2006), neuroimaging (Rubia et al., 2001; Aron et al., 2003b; Nachev et al., 2008; Pauls et al., 2012) and deep brain stimulation (Jahanshahi et al., 2000; van den Wildenberg et al., 2006; Ballanger et al., 2009; Alegre et al.,…”
Background
Cited by
Parkinson disease-associated cognitive impairment
Aarsland, D., Batzu, L., Halliday, G. M., Geurtsen, G. J., Ballard, C., Ray Chaudhuri, K., & Weintraub, D. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00280-3 · Cited by 1,371
Cognitive decline in Parkinson disease
Aarsland, D., Creese, B., Politis, M., Chaudhuri, K. R., ffytche, D. H., Weintraub, D., & Ballard, C. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.27 · Cited by 1,027
Update on treatments for nonmotor symptoms of Parkinson's disease—an evidence‐based medicine review
Seppi, K., Ray Chaudhuri, K., Coelho, M., Fox, S. H., Katzenschlager, R., Perez Lloret, S., Weintraub, D., Sampaio, C., & and the collaborators of the Parkinson's Disease Update on Non‐Motor Symptoms Study Group on behalf of the Movement Disorders Society Evidence‐Based Medicine Committee (2019) · Movement Disorders · doi:10.1002/mds.27602 · Cited by 1,007
Fractionating impulsivity: neuropsychiatric implications
Dalley, J. W., & Robbins, T. W. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2017.8 · Cited by 607
Self-citationParkinson’s disease dementia: a neural networks perspective
Gratwicke, J., Jahanshahi, M., & Foltynie, T. (2015) · Brain · doi:10.1093/brain/awv104 · Cited by 435
Metadata
- Authors
- Kehagia, A. A., Housden, C. R., Regenthal, R., Barker, R. A., Müller, U., Rowe, J., Sahakian, B. J., & Robbins, T. W.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-06-03
- Volume
- 137
- Issue
- 7
- Pages
- 1986-1997
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2108896002
- Cited by
- 139
- References
- 37
- FWCI
- 8.34
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.